경구 바이오로직스 및 바이오시밀러 의약품 시장 보고서(2026년)

Oral biologics are biologic medicines designed for oral administration to enable the effective delivery of complex biomolecules through the digestive system. Biosimilar drugs are highly comparable versions of approved biologic medicines that demonstrate similar safety, quality, and efficacy. Together, they broaden treatment options by enhancing accessibility and lowering healthcare costs.

The primary therapy types include oral biologics and biosimilar lymphocyte modulators, interleukin inhibitors, and tumor necrosis factor-alpha inhibitors. Interleukin inhibitors are immunosuppressive agents that inhibit the activity of interleukins. Interleukins are a group of cytokines produced by lymphocytes, monocytes, macrophages, and certain other cells, and they play a vital role in regulating the immune system. These therapies are used to treat a wide range of diseases such as asthma, Crohn's disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis, and others, through vaccines, proteins and peptides, monoclonal antibodies, and additional formulations. The drugs are distributed via hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have impacted the oral biologics and biosimilar drugs market by increasing costs of imported biologics, active pharmaceutical ingredients, and packaging materials. Segments like tumor necrosis factor-alpha inhibitors and interleukin inhibitors are most affected, particularly in North America and Europe, which rely heavily on imports. This has led to higher treatment costs and slower adoption rates. On the positive side, tariffs have encouraged local production, domestic R&D investment, and innovation in cost-optimized oral biologic formulations.

The oral biologics & biosimilar drugs market research report is one of a series of new reports from The Business Research Company that provides oral biologics & biosimilar drugs market statistics, including oral biologics & biosimilar drugs industry global market size, regional shares, competitors with a oral biologics & biosimilar drugs market share, detailed oral biologics & biosimilar drugs market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics & biosimilar drugs industry. This oral biologics & biosimilar drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral biologics & biosimilar drugs market size has grown exponentially in recent years. It will grow from $8.6 billion in 2025 to $10.41 billion in 2026 at a compound annual growth rate (CAGR) of 21.0%. The growth in the historic period can be attributed to limited availability of oral biologics, reliance on injectable biologics, rising prevalence of autoimmune and inflammatory diseases, increasing patient demand for cost-effective therapies, early approvals of monoclonal antibody drugs.

The oral biologics & biosimilar drugs market size is expected to see rapid growth in the next few years. It will grow to $17.17 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to development of next-generation oral biologics, expansion of biosimilar pipeline, increasing adoption of combination therapies, growing digital health platforms for patient monitoring, rising regulatory support for biosimilar approvals. Major trends in the forecast period include rising adoption of oral biologics and biosimilar drugs, increasing focus on chronic disease management using biologics, expansion of hospital and retail pharmacy distribution channels, growth in patient awareness and acceptance of biosimilars, development of targeted therapies for autoimmune and inflammatory diseases.

The increasing prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a key factor driving the growth of the oral biologics and biosimilars market. Factors including long working hours, reduced physical activity, and unhealthy dietary and lifestyle habits contribute to the rising incidence of chronic conditions, and biologics are increasingly being used for their treatment. Biologics stimulate the immune system to respond against cancer cells, thereby helping the body eliminate them. For example, in May 2023, according to a United Nations article, the share of global deaths attributed to chronic diseases is projected to rise to 70% of total deaths by 2030, with the overall global burden of chronic diseases expected to reach approximately 60%. As a result, the growing prevalence of chronic diseases is anticipated to increase demand for biologics and biosimilars, thereby driving growth in the oral biologics and biosimilar drugs market.

Leading companies in the oral biologics and biosimilar markets are emphasizing the development of innovative products, such as incretin triagonists, to improve patient outcomes, enhance drug effectiveness, and offer alternatives to injectable treatments. Incretin triagonists are therapies that simultaneously activate three hormone receptors-GLP-1, GIP, and glucagon-which play a role in regulating blood glucose levels, appetite, and metabolism. For instance, in October 2024, Rani Therapeutics Holdings Inc., a US-based biotechnology company, announced new preclinical pharmacokinetic data supporting the transenteric delivery of a GLP-1 incretin triagonist. Its RaniPill, an oral capsule designed to deliver biologics that traditionally require injections, successfully administered an incretin triagonist targeting GLP-1, GIP, and glucagon receptors, which are key targets in obesity treatment. The RaniPill demonstrated efficacy comparable to subcutaneous injections while offering a needle-free option with high bioavailability and flexible dosing, positioning it as a promising approach for obesity drug candidates.

In August 2023, Oramed Pharmaceuticals Inc., a US-based pharmaceutical company, entered into a joint venture with Hefei Tianhui Incubator of Technologies Co., Ltd. (HTIT) to develop and commercialize oral drug products. The partnership is intended to accelerate the development of innovative oral formulations, enhance patient compliance, and broaden access to orally administered therapies, thereby strengthening treatment options while supporting growth and innovation in the oral drug delivery market. Hefei Tianhui Incubator of Technologies Co., Ltd. (HTIT) is a China-based healthcare technology and innovation company focused on advancing next-generation pharmaceutical solutions.

Major companies operating in the oral biologics & biosimilar drugs market are Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., GlaxoSmithKline PLC, Concord Biotech Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral biologics and biosimilar market consist of sales of therapeutic proteins, cystic fibrosis, somatic cells, and allergenics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Biologics & Biosimilar Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oral biologics & biosimilar drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral biologics & biosimilar drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral biologics & biosimilar drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors
• 2) By Disease: Asthma; Crohn's Disease; Carcinoma; Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis and Others
• 3) By Molecule Type: Proteins & Peptides; Monoclonal Antibodies; Other Molecule Types
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Lymphocyte Modulators: Fingolimod; Ocrelizumab; Natalizumab
• 2) By Interleukin Inhibitors: Ustekinumab; Secukinumab; Guselkumab
• 3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab; Certolizumab Pegol; Golimumab
• Companies Mentioned: Novartis International AG; Rani Therapeutics Holdings Inc.; Eli Lilly and Company; AstraZeneca plc; Novo Nordisk A/S; Biocon Limited; Oramed Pharmaceuticals Inc.; BiosanaPharma; Entera Bio Ltd.; Allergan plc; Emisphere Technologies Inc.; Enteris BioPharma Inc.; Chiasma Inc.; Allena Pharmaceuticals Inc.; Gelgen Corporation; 3SBio Inc.; Innovent Biologics Inc.; GlaxoSmithKline PLC; Concord Biotech Limited; Sanofi S.A.; F. Hoffmann-La Roche Ltd.; Allergan Pharmaceuticals International Limited; Mylan N.V.; Pfizer Inc.; Sandoz International GmbH; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Oral Biologics & Biosimilar Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Oral Biologics & Biosimilar Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Oral Biologics & Biosimilar Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Oral Biologics & Biosimilar Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Oral Biologics And Biosimilar Drugs
  • 4.2.2 Increasing Focus On Chronic Disease Management Using Biologics
  • 4.2.3 Expansion Of Hospital And Retail Pharmacy Distribution Channels
  • 4.2.4 Growth In Patient Awareness And Acceptance Of Biosimilars
  • 4.2.5 Development Of Targeted Therapies For Autoimmune And Inflammatory Diseases

5. Oral Biologics & Biosimilar Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Retail Pharmacies
• 5.3 Online Pharmacies
• 5.4 Specialty Clinics
• 5.5 Biopharmaceutical Companies

6. Oral Biologics & Biosimilar Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oral Biologics & Biosimilar Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Oral Biologics & Biosimilar Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Oral Biologics & Biosimilar Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Oral Biologics & Biosimilar Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Oral Biologics & Biosimilar Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oral Biologics & Biosimilar Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oral Biologics & Biosimilar Drugs Market Segmentation

• 9.1. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
• 9.2. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
• 9.3. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types
• 9.4. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.5. Global Oral Biologics & Biosimilar Drugs Market, Sub-Segmentation Of Lymphocyte Modulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Fingolimod, Ocrelizumab, Natalizumab
• 9.6. Global Oral Biologics & Biosimilar Drugs Market, Sub-Segmentation Of Interleukin Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ustekinumab, Secukinumab, Guselkumab
• 9.7. Global Oral Biologics & Biosimilar Drugs Market, Sub-Segmentation Of Tumor Necrosis Factor-Alpha Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Adalimumab, Certolizumab Pegol, Golimumab

10. Oral Biologics & Biosimilar Drugs Market Regional And Country Analysis

• 10.1. Global Oral Biologics & Biosimilar Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Oral Biologics & Biosimilar Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oral Biologics & Biosimilar Drugs Market

• 11.1. Asia-Pacific Oral Biologics & Biosimilar Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oral Biologics & Biosimilar Drugs Market

• 12.1. China Oral Biologics & Biosimilar Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oral Biologics & Biosimilar Drugs Market

• 13.1. India Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oral Biologics & Biosimilar Drugs Market

• 14.1. Japan Oral Biologics & Biosimilar Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oral Biologics & Biosimilar Drugs Market

• 15.1. Australia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oral Biologics & Biosimilar Drugs Market

• 16.1. Indonesia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oral Biologics & Biosimilar Drugs Market

• 17.1. South Korea Oral Biologics & Biosimilar Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oral Biologics & Biosimilar Drugs Market

• 18.1. Taiwan Oral Biologics & Biosimilar Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oral Biologics & Biosimilar Drugs Market

• 19.1. South East Asia Oral Biologics & Biosimilar Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oral Biologics & Biosimilar Drugs Market

• 20.1. Western Europe Oral Biologics & Biosimilar Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oral Biologics & Biosimilar Drugs Market

• 21.1. UK Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oral Biologics & Biosimilar Drugs Market

• 22.1. Germany Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oral Biologics & Biosimilar Drugs Market

• 23.1. France Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oral Biologics & Biosimilar Drugs Market

• 24.1. Italy Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oral Biologics & Biosimilar Drugs Market

• 25.1. Spain Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oral Biologics & Biosimilar Drugs Market

• 26.1. Eastern Europe Oral Biologics & Biosimilar Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oral Biologics & Biosimilar Drugs Market

• 27.1. Russia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oral Biologics & Biosimilar Drugs Market

• 28.1. North America Oral Biologics & Biosimilar Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oral Biologics & Biosimilar Drugs Market

• 29.1. USA Oral Biologics & Biosimilar Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oral Biologics & Biosimilar Drugs Market

• 30.1. Canada Oral Biologics & Biosimilar Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oral Biologics & Biosimilar Drugs Market

• 31.1. South America Oral Biologics & Biosimilar Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oral Biologics & Biosimilar Drugs Market

• 32.1. Brazil Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oral Biologics & Biosimilar Drugs Market

• 33.1. Middle East Oral Biologics & Biosimilar Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oral Biologics & Biosimilar Drugs Market

• 34.1. Africa Oral Biologics & Biosimilar Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oral Biologics & Biosimilar Drugs Market Regulatory and Investment Landscape

36. Oral Biologics & Biosimilar Drugs Market Competitive Landscape And Company Profiles

• 36.1. Oral Biologics & Biosimilar Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Oral Biologics & Biosimilar Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Oral Biologics & Biosimilar Drugs Market Company Profiles
  • 36.3.1. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Rani Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

37. Oral Biologics & Biosimilar Drugs Market Other Major And Innovative Companies

• Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., GlaxoSmithKline PLC, Concord Biotech Limited, Sanofi S.A.

38. Global Oral Biologics & Biosimilar Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Oral Biologics & Biosimilar Drugs Market

40. Oral Biologics & Biosimilar Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Oral Biologics & Biosimilar Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Oral Biologics & Biosimilar Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Oral Biologics & Biosimilar Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer